Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of ...

SGD Pharma and Prince launch sterile Type I glass nasal vials for the US market, targeting complex chronic conditions like ...

A closer look at how robotics is reshaping pharmaceutical manufacturing, from improving quality and compliance to enabling ...

The attention economy’s most effective voices have mastered techniques that are compatible with pharma’s central mission: To communicate something that’s complex and high-stakes, and often alien to ...

The specialty pharmacy industry is in a state of transformation, fueled by the rise of complex, innovative therapies and the critical need for more robust patient support. For too long, specialty ...

Key Takeaways. LGM Pharma’s Texas expansion targets commercial suppository manufacturing and broader semi-solid/liquid ...

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...

Under this collaboration, MGI will support NUS PPS in establishing a high-performance multi-omics environment. The lab features an integrated instrument portfolio designed to provide deep insights ...

Stephen Ranjan believes teamwork is just as crucial as technology in building successful digital healthcare solutions in the pharma space Stephen Ranjan learned how to be innovative while growing up ...

AI pharmaceutical-development unicorn Deep Intelligent Pharma has recently completed a new financing round of US$60 million. New investors in this round include Trustar Capital, Jinyi Capital, and ...

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited has recently signed a cooperation agreement with a leading technology-driven e-commerce platform serving ...

Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million to ...